PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Clasificación en acciones #1418
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Precio por acción
$37.84
Capitalización bursátil
$15.65B
Cambio (1 día)
-4.42%
Cambio (1 año)
149.23%
País
TW
Comercio PharmaEssentia Corporation (6446)

Categoría

Healthcare
Historial de dividendos de PharmaEssentia Corporation (6446)
PharmaEssentia Corporation (símbolo bursátil: 6446) realizó un total de 1 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: $0.99
Rentabilidad por dividendo (TTM): 0.0012
Pagos de dividendos de PharmaEssentia Corporation (6446) desde 2025 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
2026 (TTM) $0.9898 0.00%
2025 $0.9898 0.00%
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
2026 (TTM) $1.10 0.00%
2025 $1.10 0.00%
Pagos de dividendos de empresas similares o competidoras